Detalles de la búsqueda
1.
Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.
Diabetes Obes Metab
; 25(2): 491-500, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36251282
2.
The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes.
Diabetes Obes Metab
; 25(3): 639-648, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36342041
3.
Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
Diabetes Obes Metab
; 21(3): 611-621, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30362224
4.
Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.
Diabetes Obes Metab
; 21(6): 1349-1356, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30740861
5.
Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
Diabetes Obes Metab
; 20(8): 1921-1927, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29652101
6.
The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting.
Diabetes Obes Metab
; 20(10): 2371-2378, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29797389
7.
Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
Endocr Pract
; 24(9): 796-804, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30308134
8.
Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.
Diabetes Obes Metab
; 19(6): 842-849, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28124820
9.
Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting.
Diabetes Obes Metab
; 19(12): 1773-1780, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28573681
10.
The Short-Term Cost-Effectiveness of a Fixed-Ratio Combination of Insulin Degludec and Aspart: A Cost of Control Analysis in Australia and India.
Value Health Reg Issues
; 41: 108-113, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38320441
11.
Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses.
Breast Cancer Res Treat
; 139(3): 621-37, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23722312
12.
Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
BMJ Open
; 13(9): e070473, 2023 09 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37775297
13.
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK.
Diabetes Ther
; 14(6): 1005-1021, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37120480
14.
The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.
Eur J Health Econ
; 24(6): 895-907, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36114904
15.
Evaluating the Clinical and Economic Outcomes Associated with Poor Glycemic Control in People with Type 1 Diabetes in the Netherlands.
Clinicoecon Outcomes Res
; 15: 87-96, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36778040
16.
Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide.
J Med Econ
; 26(1): 1019-1031, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37525970
17.
The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
Adv Ther
; 39(7): 3180-3198, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35553372
18.
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
Diabetol Metab Syndr
; 14(1): 32, 2022 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35164855
19.
Evaluation of the cost and medical resource use outcomes associated with nasal glucagon versus injectable glucagon for treatment of severe hypoglycemia in people with diabetes in Canada: a modeling analysis.
J Med Econ
; 25(1): 238-248, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35094622
20.
Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain.
Therap Adv Gastroenterol
; 15: 17562848221086131, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35574429